Zevaquenabant is under clinical development by Inversago Pharma and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zevaquenabant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zevaquenabant is under development for the treatment of Prader Willi syndrome, pulmonary fibrosis in Hermansky-Pudlak syndrome, idiopathic pulmonary fibrosis type 1 diabetes, diabetic nephropathy and systemic sclerosis. It is administered through oral route and inhalational route. The drug candidate is a chemically modified version of ibipinapant. It targets inducible nitric oxide synthase (iNOS) and cannabinoid-1 receptors (CB1R). It was also under development for the treatment of liver fibrosis. It is a new chemical entity (NCE)
Inversago Pharma overview
Inversago Pharma is a preclinical-stage biotech company. The company develops peripherally-restricted cannabinoid receptor 1, a G protein-coupled cannabinoid receptor that is encoded by the CNR1 gene for the treatment of Prader-Willi Syndrome, Type-1 Diabetes, obesity and other metabolic disorders such as non-alcoholic steatohepatitis.
For a complete picture of Zevaquenabant’s drug-specific PTSR and LoA scores, buy the report here.